Cargando…

Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis

BACKGROUND: This review aimed to analyze the research progress and development trends in targeted therapy (TT) for renal cancer (RC) from 2006 to 2022. METHODS: The Web of Science Core Collection database was searched using the search terms “renal cancer”, “kidney neoplasms”, “kidney cancer”, and “t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gou, Yuanqing, Fu, Yongxin, Li, Yadong, Liu, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080350/
https://www.ncbi.nlm.nih.gov/pubmed/37032755
http://dx.doi.org/10.21037/tau-23-128
_version_ 1785020903986298880
author Gou, Yuanqing
Fu, Yongxin
Li, Yadong
Liu, Chuan
author_facet Gou, Yuanqing
Fu, Yongxin
Li, Yadong
Liu, Chuan
author_sort Gou, Yuanqing
collection PubMed
description BACKGROUND: This review aimed to analyze the research progress and development trends in targeted therapy (TT) for renal cancer (RC) from 2006 to 2022. METHODS: The Web of Science Core Collection database was searched using the search terms “renal cancer”, “kidney neoplasms”, “kidney cancer”, and “targeted therapy”, and all publications were extracted. VOSviewer version 1.6.18 was used to complete the visual analysis based on the information of publications, including author, journal, subject, year, and institution. RESULTS: A total of 1,136 studies related to TT for RC were found. The top journals in this field were the Journal of Clinical Oncology, Annals of Oncology, and European Urology. Among them, the Journal of Clinical Oncology had the highest number of publications (n=35). In terms of country, the United States had the highest number of publications (n=366). The main document type was article, which accounted for 64.26% of the total publications. CONCLUSIONS: To the best of our knowledge, this is the first bibliometric analysis related to TT for RC. The annual number of publications has exhibited a steady growth trend, with the United States having the greatest contribution in this field. Through an analysis of a keyword time density map, we identified that hypoxia-inducing factor-1, drug resistance and therapeutic targets are the research hotspots and trends in this field.
format Online
Article
Text
id pubmed-10080350
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-100803502023-04-08 Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis Gou, Yuanqing Fu, Yongxin Li, Yadong Liu, Chuan Transl Androl Urol Original Article BACKGROUND: This review aimed to analyze the research progress and development trends in targeted therapy (TT) for renal cancer (RC) from 2006 to 2022. METHODS: The Web of Science Core Collection database was searched using the search terms “renal cancer”, “kidney neoplasms”, “kidney cancer”, and “targeted therapy”, and all publications were extracted. VOSviewer version 1.6.18 was used to complete the visual analysis based on the information of publications, including author, journal, subject, year, and institution. RESULTS: A total of 1,136 studies related to TT for RC were found. The top journals in this field were the Journal of Clinical Oncology, Annals of Oncology, and European Urology. Among them, the Journal of Clinical Oncology had the highest number of publications (n=35). In terms of country, the United States had the highest number of publications (n=366). The main document type was article, which accounted for 64.26% of the total publications. CONCLUSIONS: To the best of our knowledge, this is the first bibliometric analysis related to TT for RC. The annual number of publications has exhibited a steady growth trend, with the United States having the greatest contribution in this field. Through an analysis of a keyword time density map, we identified that hypoxia-inducing factor-1, drug resistance and therapeutic targets are the research hotspots and trends in this field. AME Publishing Company 2023-03-28 2023-03-31 /pmc/articles/PMC10080350/ /pubmed/37032755 http://dx.doi.org/10.21037/tau-23-128 Text en 2023 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Gou, Yuanqing
Fu, Yongxin
Li, Yadong
Liu, Chuan
Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis
title Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis
title_full Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis
title_fullStr Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis
title_full_unstemmed Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis
title_short Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis
title_sort research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080350/
https://www.ncbi.nlm.nih.gov/pubmed/37032755
http://dx.doi.org/10.21037/tau-23-128
work_keys_str_mv AT gouyuanqing researchoftargetedtherapyforrenalcancerfrom2006to2022abibliometricandvisualizedanalysis
AT fuyongxin researchoftargetedtherapyforrenalcancerfrom2006to2022abibliometricandvisualizedanalysis
AT liyadong researchoftargetedtherapyforrenalcancerfrom2006to2022abibliometricandvisualizedanalysis
AT liuchuan researchoftargetedtherapyforrenalcancerfrom2006to2022abibliometricandvisualizedanalysis